This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Various				
Inflammatory disease; multiple sclerosis (MS)	Bradykinin B1 receptor (BDKRB1)	Studies in mice suggest that agonizing BDKRB1 could be useful for treating chronic inflammatory diseases such as MS. In a mouse model of MS, a Bdkrb1 agonist significantly reduced disease symptoms and severity compared with vehicle ($p<0.01$). A Bdkrb1 antagonist significantly accelerated disease onset compared with vehicle ($p=0.01$). Next steps could include further testing in animals. <i>SciBX 2(27)</i> ; doi:10.1038/scibx.2009.1089 Published online July 16, 2009	Patent and licensing status unavailable	Schulze-Topphoff, U. <i>et al. Nat. Med.</i> ; published online June 28, 2009; doi:10.1038/nm.1980 Contact: Frauke Zipp, Charité-University Hospital Berlin, Berlin, Germany e-mail: frauke.zipp@charite.de